Biocon’s board has approved the unaudited financial results for Q2 2026, ending September 30, 2025. The board also approved the early redemption of ₹500 crore in Non-Convertible Debentures and the acquisition of Compulsorily Convertible Debentures (CCDs) in Biocon Biologics Limited (BBL) from Edelweiss for ₹300 crore. The company also plans to issue commercial papers up to ₹550 crore.
Financial Highlights for Q2 2026
Biocon’s Board of Directors has reviewed and approved the unaudited standalone financial results for the quarter ending September 30, 2025. Key figures from the statement include:
- Revenue from operations: ₹5,833 million
- Total Income: ₹7,171 million
- Profit before tax: ₹857 million
- Net Profit: ₹709 million
The earnings per share is ₹0.55 (basic and diluted).
CCD Acquisition from Edelweiss
The board has approved the acquisition of 1,06,86,044 unlisted, secured, Compulsorily Convertible Debentures (CCDs) of Biocon Biologics Limited (BBL) from ESOF III Investment Fund and EAAA India Alternatives Limited (Edelweiss) with a face value of ₹10 each. The acquisition is valued at ₹300 crore and is expected to be completed on or before January 30, 2026, subject to necessary approvals. This acquisition will increase the company’s holding in BBL by approximately 65 basis points.
Early Redemption of Non-Convertible Debentures
The board has authorized the early full redemption of 50,000 unlisted, secured, rated, redeemable Non-Convertible Debentures (NCDs) with a face value of ₹1,00,000 each, totaling ₹500 crore. These NCDs were issued on a private placement basis on May 19, 2023, and the redemption is subject to receipt of necessary approvals or consents on or before January 31, 2026.
Issuance of Commercial Papers
The board has also approved the issuance of Commercial Papers up to an amount not exceeding ₹550 crore in one or more tranches on a private placement basis.
Source: BSE
